Use of probiotics in gastrointestinal disorders: What to recommend?

Therapeutic Advances in Gastroenterology

Volumn 3, Issue 5, 2010, Pages 307-319

  Verna, Elizabeth C ^a   Lucak, Susan ^a  

^a Department of Neurology and the Taub Institute for Research on Alzheimer's Disease and the Aging Brain   (United States)

Author keywords

Antibiotic associated diarrhea; Clostridium difficile colitis; Crohn's disease; Irritable bowel syndrome; Pouchitis; Probiotics; Review; Ulcerative colitis

Indexed keywords

ANTIBIOTIC AGENT; INULIN; METRONIDAZOLE; PROBIOTIC AGENT; SYNBIOTIC AGENT; VANCOMYCIN;

BACTERIAL METABOLISM; BACTERIAL STRAIN; BIFIDOBACTERIUM ANIMALIS; BIFIDOBACTERIUM LONGUM; BIFIDOBACTERIUM LONGUM INFANTIS; CLOSTRIDIUM DIFFICILE INFECTION; COLONY FORMATION; CROHN DISEASE; DIARRHEA; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; ENTERITIS; ESCHERICHIA COLI; HUMAN; ILEITIS; INFECTIOUS DIARRHEA; INGESTION; IRRITABLE COLON; LACTIC ACID BACTERIUM; LACTOBACILLUS CASEI; LACTOBACILLUS REUTERI; LACTOBACILLUS RHAMNOSUS; LACTOBACILLUS SALIVARIUS; MICROFLORA; NONHUMAN; PRIORITY JOURNAL; REVIEW; SACCHAROMYCES BOULARDII; STOMACH FUNCTION; TREATMENT DURATION; ULCERATIVE COLITIS;

EID: 77956240735     PISSN: 1756283X     EISSN: None     Source Type: Journal    
DOI: 10.1177/1756283X10373814     Document Type: Review

References (112)

1. Allen, S.J., Okoko, B., Martinez, E., Gregorio, G. and Dans, L.F. ( 2004) Probiotics for treating infectious diarrhoea. Cochrane Database Syst Rev 2: CD003048.
2. Bassetti, S., Frei, R. and Zimmerli, W. ( 1998) Fungemia with Saccharomyces cerevisiae after treatment with Saccharomyces boulardii. Am J Med 105: 71-72.
3. Besselink, M.G., van Santvoort, H.C., Buskens, E., Boermeester, M.A., van Goor, H., Timmerman, H.M. et al. (2008) Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial. Lancet 371: 651-659.
4. Borchers, A.T., Selmi, C., Meyers, F.J., Keen, C.L. and Gershwin, M.E. ( 2009) Probiotics and immunity. J Gastroenterol 44: 26-46.
5. Borruel, N., Carol, M., Casellas, F., Antolin, M., de Lara, F., Espin, E. et al. (2002) Increased mucosal tumour necrosis factor alpha production in Crohn's disease can be downregulated ex vivo by probiotic bacteria. Gut 51: 659-664.
6. Boyle, R.J., Robins-Browne, R.M. and Tang, M.L. ( 2006) Probiotic use in clinical practice: what are the risks? Am J Clin Nutr 83: 1256-1264, quiz 1446-1257.
7. Brenner, D.M., Moeller, M.J., Chey, W.D. and Schoenfeld, P.S. ( 2009) The utility of probiotics in the treatment of irritable bowel syndrome: a systematic review. Am J Gastroenterol 104: 1033-1049, quiz 1050.
8. Candela, M., Seibold, G., Vitali, B., Lachenmaier, S., Eikmanns, B.J. and Brigidi, P. ( 2005) Real-time PCR quantification of bacterial adhesion to Caco-2 cells: competition between bifidobacteria and enteropathogens. Res Microbiol 156: 887-895.
9. Cannon, J.P., Lee, T.A., Bolanos, J.T. and Danziger, L.H. ( 2005) Pathogenic relevance of Lactobacillus: a retrospective review of over 200 cases. Eur J Clin Microbiol Infect Dis 24: 31-40.
10. Cassone, M., Serra, P., Mondello, F., Girolamo, A., Scafetti, S., Pistella, E. et al. (2003) Outbreak of Saccharomyces cerevisiae subtype boulardii fungemia in patients neighboring those treated with a probiotic preparation of the organism. J Clin Microbiol 41: 5340-5343.
11. Cesaro, S., Chinello, P., Rossi, L. and Zanesco, L. ( 2000) Saccharomyces cerevisiae fungemia in a neutropenic patient treated with Saccharomyces boulardii. Support Care Cancer 8: 504-505.
12. Cherifi, S., Robberecht, J. and Miendje, Y. ( 2004) Saccharomyces cerevisiae fungemia in an elderly patient with Clostridium difficile colitis. Acta Clin Belg 59: 223-224.
13. Chermesh, I., Tamir, A., Reshef, R., Chowers, Y., Suissa, A., Katz, D. et al. (2007) Failure of Synbiotic 2000 to prevent postoperative recurrence of Crohn's disease. Dig Dis Sci 52: 385-389.
14. Collado, M.C., Hernandez, M. and Sanz, Y. ( 2005) Production of bacteriocin-like inhibitory compounds by human fecal Bifidobacterium strains. J Food Prot 68: 1034-1040.
15. Collado, M.C., Meriluoto, J. and Salminen, S. ( 2007) Role of commercial probiotic strains against human pathogen adhesion to intestinal mucus. Lett Appl Microbiol 45: 454-460.
16. Collins, S.M., Denou, E., Verdu, E.F. and Bercik, P. (2009) The putative role of the intestinal microbiota in the irritable bowel syndrome. Dig Liver Dis 41: 850-853.
17. Cotter, P.D., Hill, C. and Ross, R.P. ( 2005) Bacteriocins: developing innate immunity for food. Nat Rev Microbiol 3: 777-788.
18. Cremonini, F., Di Caro, S., Nista, E.C., Bartolozzi, F., Capelli, G., Gasbarrini, G. et al. (2002) Meta-analysis: the effect of probiotic administration on antibiotic-associated diarrhoea. Aliment Pharmacol Ther 16: 1461-1467.
19. D'Souza, A.L., Rajkumar, C., Cooke, J. and Bulpitt, C.J. ( 2002) Probiotics in prevention of antibiotic associated diarrhoea: meta-analysis. BMJ 324: 1361.
20. de Groote, M.A., Frank, D.N., Dowell, E., Glode, M.P. and Pace, N.R. ( 2005) Lactobacillus rhamnosus GG bacteremia associated with probiotic use in a child with short gut syndrome. Pediatr Infect Dis J 24: 278-280.
21. Dinan, T.G., Quigley, E.M., Ahmed, S.M., Scully, P., O'Brien, S., O'Mahony, L. et al. (2006) Hypothalamic-pituitary-gut axis dysregulation in irritable bowel syndrome: plasma cytokines as a potential biomarker? Gastroenterology 130: 304-311.
22. Enck, P., Zimmermann, K., Rusch, K., Schwiertz, A., Klosterhalfen, S. and Frick, J.S. (2009) The effects of ageing on the colonic bacterial microflora in adults. Z Gastroenterol 47: 653-658.
23. Focareta, A., Paton, J.C., Morona, R., Cook, J. and Paton, A.W. ( 2006) A recombinant probiotic for treatment and prevention of cholera. Gastroenterology 130: 1688-1695.
24. Fredenucci, I., Chomarat, M., Boucaud, C. and Flandrois, J.P. ( 1998) Saccharomyces boulardii fungemia in a patient receiving Ultra-levure therapy. Clin Infect Dis 27: 222-223.
25. Fujimori, S., Tatsuguchi, A., Gudis, K., Kishida, T., Mitsui, K., Ehara, A. et al. (2007) High dose probiotic and prebiotic cotherapy for remission induction of active Crohn's disease. J Gastroenterol Hepatol 22: 1199-1204.
26. Furrie, E., Macfarlane, S., Kennedy, A., Cummings, J.H., Walsh, S.V., O'Neil, D.A. et al. (2005) Synbiotic therapy (Bifidobacterium longum/Synergy 1) initiates resolution of inflammation in patients with active ulcerative colitis: a randomised controlled pilot trial. Gut 54: 242-249.
27. Gionchetti, P., Rizzello, F., Helwig, U., Venturi, A., Lammers, K.M., Brigidi, P. et al. (2003) Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. Gastroenterology 124: 1202-1209.
28. Gionchetti, P., Rizzello, F., Morselli, C., Poggioli, G., Tambasco, R., Calabrese, C. et al. (2007) High-dose probiotics for the treatment of active pouchitis. Dis Colon Rectum 50: 2075-2082, discussion 2082-2074.
29. Gionchetti, P., Rizzello, F., Venturi, A., Brigidi, P., Matteuzzi, D., Bazzocchi, G. et al. (2000) Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology 119: 305-309.
30. Gordon, S. ( 2008) Elie Metchnikoff: father of natural immunity. Eur J Immunol 38: 3257-3264.
31. Grajek, W., Olejnik, A. and Sip, A. ( 2005) Probiotics, prebiotics and antioxidants as functional foods. Acta Biochim Pol 52: 665-671.
32. Guslandi, M., Mezzi, G., Sorghi, M. and Testoni, P.A. ( 2000) Saccharomyces boulardii in maintenance treatment of Crohn's disease. Dig Dis Sci 45: 1462-1464.
33. Hart, A.L., Lammers, K., Brigidi, P., Vitali, B., Rizzello, F., Gionchetti, P. et al. (2004) Modulation of human dendritic cell phenotype and function by probiotic bacteria. Gut 53: 1602-1609.
34. Hennequin, C., Kauffmann-Lacroix, C., Jobert, A., Viard, J.P., Ricour, C., Jacquemin, J.L. et al. (2000) Possible role of catheters in Saccharomyces boulardii fungemia. Eur J Clin Microbiol Infect Dis 19: 16-20.
35. Henry, S., D'Hondt, L., Andre, M., Holemans, X. and Canon, J.L. ( 2004) Saccharomyces cerevisiae fungemia in a head and neck cancer patient: a case report and review of the literature. Acta Clin Belg 59: 220-222.
36. Hickson, M., D'Souza, A.L., Muthu, N., Rogers, T.R., Want, S., Rajkumar, C. et al. (2007) Use of probiotic Lactobacillus preparation to prevent diarrhoea associated with antibiotics: randomised double blind placebo controlled trial. BMJ 335: 80.
37. Inohara, N., Ogura, Y., Fontalba, A., Gutierrez, O., Pons, F., Crespo, J. et al. (2003) Host recognition of bacterial muramyl dipeptide mediated through NOD2. Implications for Crohn's disease. J Biol Chem 278: 5509-5512.
38. Ishikawa, H., Akedo, I., Umesaki, Y., Tanaka, R., Imaoka, A. and Otani, T. ( 2003) Randomized controlled trial of the effect of bifidobacteria-fermented milk on ulcerative colitis. J Am Coll Nutr 22: 56-63.
39. Kamil, R., Geier, M.S., Butler, R.N. and Howarth, G.S. ( 2007) Lactobacillus rhamnosus GG exacerbates intestinal ulceration in a model of indomethacininduced enteropathy. Dig Dis Sci 52: 1247-1252.
40. Kassinen, A., Krogius-Kurikka, L., Makivuokko, H., Rinttila, T., Paulin, L., Corander, J. et al. (2007) The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects. Gastroenterology 133: 24-33.
41. Kato, K., Mizuno, S., Umesaki, Y., Ishii, Y., Sugitani, M., Imaoka, A. et al. (2004) Randomized placebo-controlled trial assessing the effect of bifidobacteria-fermented milk on active ulcerative colitis. Aliment Pharmacol Ther 20: 1133-1141.
42. Kim, H.J., Camilleri, M., McKinzie, S., Lempke, M.B., Burton, D.D., Thomforde, G.M. et al. (2003) A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 17: 895-904.
43. Kim, H.J., Vazquez Roque, M.I., Camilleri, M., Stephens, D., Burton, D.D., Baxter, K. et al. (2005) A randomized controlled trial of a probiotic combination VSL# 3 and placebo in irritable bowel syndrome with bloating. Neurogastroenterol Motil 17: 687-696.
44. Kobayashi, K.S., Chamaillard, M., Ogura, Y., Henegariu, O., Inohara, N., Nunez, G. et al. (2005) Nod2-dependent regulation of innate and adaptive immunity in the intestinal tract. Science 307: 731-734.
45. Komanduri, S., Gillevet, P.M., Sikaroodi, M., Mutlu, E. and Keshavarzian, A. ( 2007) Dysbiosis in pouchitis: evidence of unique microfloral patterns in pouch inflammation. Clin Gastroenterol Hepatol 5: 352-360.
46. Kruis, W., Fric, P., Pokrotnieks, J., Lukas, M., Fixa, B., Kascak, M. et al. (2004) Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut 53: 1617-1623.
47. Kruis, W., Schutz, E., Fric, P., Fixa, B., Judmaier, G. and Stolte, M. ( 1997) Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 11: 853-858.
48. Kuisma, J., Mentula, S., Jarvinen, H., Kahri, A., Saxelin, M. and Farkkila, M. ( 2003) Effect of Lactobacillus rhamnosus GG on ileal pouch inflammation and microbial flora. Aliment Pharmacol Ther 17: 509-515.
49. Kunz, A.N., Fairchok, M.P. and Noel, J.M. ( 2005) Lactobacillus sepsis associated with probiotic therapy. Pediatrics 116: 517, author reply 517-518.
50. Kunz, A.N., Noel, J.M. and Fairchok, M.P. ( 2004) Two cases of Lactobacillus bacteremia during probiotic treatment of short gut syndrome. J Pediatr Gastroenterol Nutr 38: 457-458.
51. Land, M.H., Rouster-Stevens, K., Woods, C.R., Cannon, M.L., Cnota, J. and Shetty, A.K. ( 2005) Lactobacillus sepsis associated with probiotic therapy. Pediatrics 115: 178-181.
52. Lawton, E.M., Ross, R.P., Hill, C. and Cotter, P.D. ( 2007) Two-peptide lantibiotics: a medical perspective. Mini Rev Med Chem 7: 1236-1247.
53. Lestin, F., Pertschy, A. and Rimek, D. ( 2003) [Fungemia after oral treatment with Saccharomyces boulardii in a patient with multiple comorbidities]. Dtsch Med Wochenschr 128: 2531-2533.
54. Lherm, T., Monet, C., Nougiere, B., Soulier, M., Larbi, D., Le Gall, C. et al. (2002) Seven cases of fungemia with Saccharomyces boulardii in critically ill patients. Intensive Care Med 28 (6): 797-801.
55. Liebregts, T., Adam, B., Bredack, C., Roth, A., Heinzel, S., Lester, S. et al. (2007) Immune activation in patients with irritable bowel syndrome. Gastroenterology 132: 913-920.
56. Lin, H.C. ( 2004) Small intestinal bacterial overgrowth: a framework for understanding irritable bowel syndrome. JAMA 292 (7): 852-858.
57. Lin, Y.P., Thibodeaux, C.H., Pena, J.A., Ferry, G.D. and Versalovic, J. ( 2008) Probiotic Lactobacillus reuteri suppress proinflammatory cytokines via c-Jun. Inflamm Bowel Dis 14: 1068-1083.
58. Mackay, A.D., Taylor, M.B., Kibbler, C.C. and Hamilton-Miller, J.M. ( 1999) Lactobacillus endocarditis caused by a probiotic organism. Clin Microbiol Infect 5: 290-292.
59. Macsharry, J., O'Mahony, L., Fanning, A., Bairead, E., Sherlock, G., Tiesman, J. et al. (2008) Mucosal cytokine imbalance in irritable bowel syndrome. Scand J Gastroenterol 43: 1467-1476.
60. Makras, L., Triantafyllou, V., Fayol-Messaoudi, D., Adriany, T., Zoumpopoulou, G., Tsakalidou, E. et al. (2006) Kinetic analysis of the antibacterial activity of probiotic lactobacilli towards Salmonella enterica serovar Typhimurium reveals a role for lactic acid and other inhibitory compounds. Res Microbiol 157: 241-247.
61. Malchow, H.A. ( 1997) Crohn's disease and Escherichia coli A new approach in therapy to maintain remission of colonic Crohn's disease? J Clin Gastroenterol 25: 653-658.
62. Mallon, P., McKay, D., Kirk, S. and Gardiner, K. ( 2007) Probiotics for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 4: CD005573.
63. Marteau, P., Lemann, M., Seksik, P., Laharie, D., Colombel, J.F., Bouhnik, Y. et al. (2006) Ineffectiveness of Lactobacillus johnsonii LA 1 for prophylaxis of postoperative recurrence in Crohn's disease: a randomised, double blind, placebo controlled GETAID trial. Gut 55: 842-847.
64. Matsumoto, S., Hara, T., Hori, T., Mitsuyama, K., Nagaoka, M., Tomiyasu, N. et al. (2005) Probiotic Lactobacillus-induced improvement in murine chronic inflammatory bowel disease is associated with the down-regulation of pro-inflammatory cytokines in lamina propria mononuclear cells. Clin Exp Immunol 140: 417-426.
65. Matto, J., Malinen, E., Suihko, M.L., Alander, M., Palva, A. and Saarela, M. ( 2004) Genetic heterogeneity and functional properties of intestinal bifidobacteria. J Appl Microbiol 97: 459-470.
66. McCarthy, J., O'Mahony, L., O'Callaghan, L., Sheil, B., Vaughan, E.E., Fitzsimons, N. et al. (2003) Double blind, placebo controlled trial of two probiotic strains in interleukin 10 knockout mice and mechanistic link with cytokine balance. Gut 52 (7): 975-980.
67. McFarland, L.V. ( 2006) Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease. Am J Gastroenterol 101: 812-822.
68. McFarland, L.V., Surawicz, C.M., Greenberg, R.N., Fekety, R., Elmer, G.W., Moyer, K.A. et al. (1994) A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA 271: 1913-1918.
69. Mimura, T., Rizzello, F., Helwig, U., Poggioli, G., Schreiber, S., Talbot, I.C. et al. (2004) Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut 53: 108-114.
70. Moayyedi, P., Ford, A.C., Talley, N.J., Cremonini, F., Foxx-Orenstein, A.E., Brandt, L.J. et al. (2010) The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review. Gut 59: 325-332.
71. Mukai, T., Kaneko, S., Matsumoto, M. and Ohori, H. ( 2004) Binding of Bifidobacterium bifidum and Lactobacillus reuteri to the carbohydrate moieties of intestinal glycolipids recognized by peanut agglutinin. Int J Food Microbiol 90: 357-362.
72. Nance, D.M. and Sanders, V.M. ( 2007) Autonomic innervation and regulation of the immune system (1987-2007). Brain Behav Immun 21: 736-745.
73. Niault, M., Thomas, F., Prost, J., Ansari, F.H. and Kalfon, P. ( 1999) Fungemia due to Saccharomyces species in a patient treated with enteral Saccharomyces boulardii. Clin Infect Dis 28: 930.
74. Nissle, A. ( 1959) [Explanations of the significance of colonic dysbacteria & the mechanism of action of E. coli therapy (mutaflor)]. Medizinische 4: 1017-1022.
75. O'Hara, A.M. and Shanahan, F. ( 2006) The gut flora as a forgotten organ. EMBO Rep 7: 688-693.
76. O'Mahony, L., McCarthy, J., Kelly, P., Hurley, G., Luo, F., Chen, K. et al. (2005) Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology 128: 541-551.
77. Pathmakanthan, S., Li, C.K., Cowie, J. and Hawkey, C.J. ( 2004) Lactobacillus plantarum 299: beneficial in vitro immunomodulation in cells extracted from inflamed human colon. J Gastroenterol Hepatol 19: 166-173.
78. Paton, A.W., Jennings, M.P., Morona, R., Wang, H., Focareta, A., Roddam, L.F. et al. (2005) Recombinant probiotics for treatment and prevention of enterotoxigenic Escherichia coli diarrhea. Gastroenterology 128: 1219-1228.
79. Pena, J.A. and Versalovic, J. ( 2003) Lactobacillus rhamnosus GG decreases TNF-alpha production in lipopolysaccharide-activated murine macrophages by a contact-independent mechanism. Cell Microbiol 5: 277-285.
80. Perapoch, J., Planes, A.M., Querol, A., Lopez, V., Martinez-Bendayan, I., Tormo, R. et al. (2000) Fungemia with Saccharomyces cerevisiae in two newborns, only one of whom had been treated with ultralevura. Eur J Clin Microbiol Infect Dis 19: 468-470.
81. Pillai, A. and Nelson, R. ( 2008) Probiotics for treatment of Clostridium difficile-associated colitis in adults. Cochrane Database Syst Rev 1: CD004611.
82. Pletincx, M., Legein, J. and Vandenplas, Y. ( 1995) Fungemia with Saccharomyces boulardii in a 1-year-old girl with protracted diarrhea. J Pediatr Gastroenterol Nutr 21: 113-115.
83. Posserud, I., Stotzer, P.O., Bjornsson, E.S., Abrahamsson, H. and Simren, M. ( 2007) Small intestinal bacterial overgrowth in patients with irritable bowel syndrome. Gut 56: 802-808.
84. Prantera, C., Scribano, M.L., Falasco, G., Andreoli, A. and Luzi, C. ( 2002) Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn's disease: a randomised controlled trial with Lactobacillus GG. Gut 51: 405-409.
85. Quigley, E.M. and Flourie, B. ( 2007) Probiotics and irritable bowel syndrome: a rationale for their use and an assessment of the evidence to date. Neurogastroenterol Motil 19: 166-172.
86. Rahimi, R., Nikfar, S., Rahimi, F., Elahi, B., Derakhshani, S., Vafaie, M. et al. (2008) A meta-analysis on the efficacy of probiotics for maintenance of remission and prevention of clinical and endoscopic relapse in Crohn's disease. Dig Dis Sci 53: 2524-2531.
87. Rautio, M., Jousimies-Somer, H., Kauma, H., Pietarinen, I., Saxelin, M., Tynkkynen, S. et al. (1999) Liver abscess due to a Lactobacillus rhamnosus strain indistinguishable from L. rhamnosus strain GG. Clin Infect Dis 28: 1159-1160.
88. Rembacken, B.J., Snelling, A.M., Hawkey, P.M., Chalmers, D.M. and Axon, A.T. ( 1999) Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet 354: 635-639.
89. Rijnders, B.J., van Wijngaerden, E., Verwaest, C. and Peetermans, W.E. ( 2000) Saccharomyces fungemia complicating Saccharomyces boulardii treatment in a non-immunocompromised host. Intensive Care Med 26: 825.
90. Riquelme, A.J., Calvo, M.A., Guzman, A.M., Depix, M.S., Garcia, P., Perez, C. et al. (2003) Saccharomyces cerevisiae fungemia after Saccharomyces boulardii treatment in immunocompromised patients. J Clin Gastroenterol 36: 41-43.
91. Rolfe, V.E., Fortun, P.J., Hawkey, C.J. and Bath-Hextall, F. ( 2006) Probiotics for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev 4: CD004826.
92. Roselli, M., Finamore, A., Britti, M.S. and Mengheri, E. ( 2006) Probiotic bacteria Bifidobacterium animalis MB 5 and Lactobacillus rhamnosus GG protect intestinal Caco-2 cells from the inflammation-associated response induced by enterotoxigenic Escherichia coli K88. Br J Nutr 95: 1177-1184.
93. Rousseaux, C., Thuru, X., Gelot, A., Barnich, N., Neut, C., Dubuquoy, L. et al. (2007) Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors. Nat Med 13: 35-37.
94. Sartor, R.B. ( 2004) Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics. Gastroenterology 126: 1620-1633.
95. Saxelin, M., Chuang, N.H., Chassy, B., Rautelin, H., Makela, P.H., Salminen, S. et al. (1996) Lactobacilli and bacteremia in southern Finland, 1989-1992. Clin Infect Dis 22: 564-566.
96. Schultz, M., Timmer, A., Herfarth, H.H., Sartor, R.B., Vanderhoof, J.A. and Rath, H.C. ( 2004) Lactobacillus GG in inducing and maintaining remission of Crohn's disease. BMC Gastroenterol 4: 5.
97. Servin, A.L. ( 2004) Antagonistic activities of lactobacilli and bifidobacteria against microbial pathogens. FEMS Microbiol Rev 28: 405-440.
98. Shanahan, F. ( 2007) Irritable bowel syndrome: shifting the focus toward the gut microbiota. Gastroenterology 133: 340-342.
99. Sherman, P.M., Johnson-Henry, K.C., Yeung, H.P., Ngo, P.S., Goulet, J. and Tompkins, T.A. ( 2005) Probiotics reduce enterohemorrhagic Escherichia coli O157:H7- and enteropathogenic E. coli O127:H6induced changes in polarized T 84 epithelial cell monolayers by reducing bacterial adhesion and cytoskeletal rearrangements. Infect Immun 73: 5183-5188.
100. Smits, H.H., Engering, A., van der Kleij, D., de Jong, E.C., Schipper, K., van Capel, T.M. et al. (2005) Selective probiotic bacteria induce IL-10-producing regulatory T cells in vitro by modulating dendritic cell function through dendritic cell-specific intercellular adhesion molecule 3-grabbing nonintegrin. J Allergy Clin Immunol 115: 1260-1267.
101. Spiller, R.C., Jenkins, D., Thornley, J.P., Hebden, J.M., Wright, T., Skinner, M. et al. (2000) Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome. Gut 47: 804-811.
102. Sturm, A., Rilling, K., Baumgart, D.C., Gargas, K., Abou-Ghazale, T., Raupach, B. et al. (2005) Escherichia coli Nissle 1917 distinctively modulates T-cell cycling and expansion via toll-like receptor 2 signaling. Infect Immun 73: 1452-1465.
103. Szajewska, H. and Mrukowicz, J. ( 2005) Meta-analysis: non-pathogenic yeast Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea. Aliment Pharmacol Ther 22: 365-372.
104. Takahashi, N., Xiao, J.Z., Miyaji, K., Yaeshiima, T., Hiramatsu, A., Iwatsuki, K. et al. (2004) Selection of acid tolerant bifidobacteria and evidence for a low-pHinducible acid tolerance response in Bifidobacterium longum. J Dairy Res 71: 340-345.
105. Tursi, A., Brandimarte, G., Giorgetti, G.M., Forti, G., Modeo, M.E. and Gigliobianco, A. ( 2004) Low-dose balsalazide plus a high-potency probiotic preparation is more effective than balsalazide alone or mesalazine in the treatment of acute mild-to-moderate ulcerative colitis. Med Sci Monit 10: P1126-P1131.
106. van Gossum, A., Dewit, O., Louis, E., de Hertogh, G., Baert, F., Fontaine, F. et al. (2007) Multicenter randomized-controlled clinical trial of probiotics (Lactobacillus johnsonii, LA1) on early endoscopic recurrence of Crohn's disease after lleo-caecal resection. Inflamm Bowel Dis 13: 135-142.
107. Vanderpool, C., Yan, F. and Polk, D.B. ( 2008) Mechanisms of probiotic action: Implications for therapeutic applications in inflammatory bowel diseases. Inflamm Bowel Dis 14: 1585-1596.
108. Vaughan, R.B. ( 1965) The romantic rationalist: a study of Elie Metchnikoff. Med Hist 9: 201-215.
109. Wagner, R.D., Pierson, C., Warner, T., Dohnalek, M., Farmer, J., Roberts, L. et al. (1997) Biotherapeutic effects of probiotic bacteria on candidiasis in immunodeficient mice. Infect Immun 65: 4165-4172.
110. Yan, F., Cao, H., Cover, T.L., Whitehead, R., Washington, M.K. and Polk, D.B. ( 2007) Soluble proteins produced by probiotic bacteria regulate intestinal epithelial cell survival and growth. Gastroenterology 132: 562-575.
111. Zigra, P.I., Maipa, V.E. and Alamanos, Y.P. ( 2007) Probiotics and remission of ulcerative colitis: a systematic review. Neth J Med 65: 411-418.
112. Zocco, M.A., dal Verme, L.Z., Cremonini, F., Piscaglia, A.C., Nista, E.C., Candelli, M. et al. (2006) Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 23: 1567-1574.